Drugs /

eluvixtamab

Back to Drugs List

Overview

NCI Definition [1]:
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.

Clinical Trials

View Clinical Trials for eluvixtamab

Eluvixtamab has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating eluvixtamab, 2 are phase 1 (1 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for eluvixtamab clinical trials.

Acute myeloid leukemia and myelodysplastic syndromes are the most common diseases being investigated in eluvixtamab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Eluvixtamab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Eluvixtamab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating eluvixtamab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
amg 330, cd33/cd3-directed bispecific t-cell engager antibody amg 330, bite antibody amg 330, bispecific t-cell engager antibody amg 330, amg330, anti-cd33/cd3 bite antibody amg 330
Drug Target(s) [2]:
CD3, CD33
NCIT ID [1]:
C123332

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.